Chris Garabedian
Chairman & CEO
Description:
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group to their healthcare practice group.
Summary:
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof ...
Number of Registered Investments:1
Contact Details:
- Address: Boston, Massachusetts, United States
- No email is provided
Location:Boston, Massachusetts, United States
Email is Not Provided
Phone Number:Boston, Massachusetts, United States
Updated August 2023. This content was crafted by an associate of Najafi Capital (“Najafi”) and is presented strictly for informational objectives. The details on this page neither advocate for nor dissuade the subscription, acquisition, or sale of any security or offering. The material Najafi evaluates for project owner screening and due diligence stems directly from the project owner presenting the investment opportunity. While Najafi perceives the information to have been sourced from trustworthy channels, there is no absolute assurance, warranty, or representation concerning its authenticity. Najafi renounces any liability regarding content provided by the project owner, inclusive of the data utilized to fulfill elements outlined on this page. Najafi is not accountable for the precision, legality, or the affirmation of subsequent details shared by the project owner.
Prospective investors are urged to perform their individual due diligence and authenticate the provided data. Investing inherently encompasses risks, inclusive of the potential loss of capital invested. All investors are recommended to ponder over these aspects in tandem with a chosen professional consultant to ascertain the suitability of an investment.
English 
Polish 